Herpes DNAemia and TTV Viraemia in Intensive Care Unit Critically Ill Patients: A Single-Centre Prospective Longitudinal Study.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2021
Historique:
received: 27 04 2021
accepted: 12 10 2021
entrez: 19 11 2021
pubmed: 20 11 2021
medline: 22 12 2021
Statut: epublish

Résumé

We analysed blood DNAemia of TTV and four herpesviruses (CMV, EBV, HHV6, and HSV-1) in the REAnimation Low Immune Status Marker (REALISM) cohort of critically ill patients who had presented with either sepsis, burns, severe trauma, or major surgery. The aim was to identify common features related to virus and injury-associated pathologies and specific features linking one or several viruses to a particular pathological context. Overall and individual viral DNAemia were measured over a month using quantitative PCR assays from the 377 patients in the REALISM cohort. These patients were characterised by clinical outcomes [severity scores, mortality, Intensive Care Unit (ICU)-acquired infection (IAI)] and 48 parameters defining their host response after injury (cell populations, immune functional assays, and biomarkers). Association between viraemic event and clinical outcomes or immune markers was assessed using χ The cumulative incidence of viral DNAemia increased from below 4% at ICU admission to 35% for each herpesvirus during the first month. EBV, HSV1, HHV6, and CMV were detected in 18%, 12%, 10%, and 9% of patients, respectively. The incidence of high TTV viraemia (>10,000 copies/ml) increased from 11% to 15% during the same period. Herpesvirus viraemia was associated with severity at admission; CMV and HHV6 viraemia correlated with mortality during the first week and over the month. The presence of individual herpesvirus during the first month was significantly associated (p < 0.001) with the occurrence of IAI, whilst herpesvirus DNAemia coupled with high TTV viraemia during the very first week was associated with IAI. Herpesvirus viraemia was associated with a lasting exacerbated host immune response, with concurrent profound immune suppression and hyper inflammation, and delayed return to immune homeostasis. The percentage of patients presenting with herpesvirus DNAemia was significantly higher in sepsis than in all other groups. Primary infection in the hospital and high IL10 levels might favour EBV and CMV reactivation. In this cohort of ICU patients, phenotypic differences were observed between TTV and herpesviruses DNAemia. The higher prevalence of herpesvirus DNAemia in sepsis hints at further studies that may enable a better

Identifiants

pubmed: 34795661
doi: 10.3389/fimmu.2021.698808
pmc: PMC8593420
doi:

Banques de données

ClinicalTrials.gov
['NCT02638779']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

698808

Informations de copyright

Copyright © 2021 Mallet, Diouf, Meunier, Perret, Reynier, Leissner, Quemeneur, Griffiths, Moucadel, Pachot, Venet, Monneret, Lepape, Rimmelé, Tan, Brengel-Pesce and Textoris.

Déclaration de conflit d'intérêts

FM, VM, AP, KB-P, and JT are employees of bioMérieux SA, an in vitro diagnostic company. LD was employed by IVIDATA. BM was employed by company Soladis Inc. FV, GM, AP, TR, and JT are employees of Hospices Civils de Lyon. FM, LD, BM, VM, AP, FV, GM, AL, TR, KB-P, and JT work in a joint research unit, co-funded by the Hospices Civils de Lyon and bioMérieux. LT is an employee of and hold stock and shares in GlaxoSmithKline. LQ is an employee of Sanofi Pasteur. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

BMC Infect Dis. 2018 Jun 28;18(1):289
pubmed: 29954328
BMC Biol. 2020 Jun 4;18(1):55
pubmed: 32493363
Clin Microbiol Infect. 2020 Oct;26(10):1406-1410
pubmed: 31972321
Crit Care Med. 2009 Jun;37(6):1850-7
pubmed: 19384219
PLoS One. 2014 Jun 11;9(2):e98819
pubmed: 24919177
J Infect Dis. 2020 Jul 21;222(Suppl 2):S84-S95
pubmed: 32691839
BMC Genomics. 2018 Jul 5;19(1):522
pubmed: 29976163
Pediatr Crit Care Med. 2018 Jan;19(1):e14-e22
pubmed: 29189638
PLoS Pathog. 2017 Mar 22;13(3):e1006292
pubmed: 28328962
Lancet Infect Dis. 2013 Mar;13(3):260-8
pubmed: 23427891
Crit Care Med. 2015 Jul;43(7):1415-22
pubmed: 25821919
Sci Rep. 2020 Jun 17;10(1):9838
pubmed: 32555213
Clin Infect Dis. 2017 May 1;64(9):1204-1210
pubmed: 28158551
JAMA. 2008 Jul 23;300(4):413-22
pubmed: 18647984
J Virol. 2020 Apr 16;94(9):
pubmed: 32051273
Immunol Rev. 2016 Nov;274(1):330-353
pubmed: 27782333
JAMA Intern Med. 2020 Feb 1;180(2):263-272
pubmed: 31841577
J Clin Virol. 2010 Feb;47(2):189-92
pubmed: 20034850
Transplantation. 2007 Feb 27;83(4):433-8
pubmed: 17318076
Viruses. 2018 Nov 14;10(11):
pubmed: 30441786
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Crit Care. 2020 Mar 18;24(1):96
pubmed: 32188504
J Med Virol. 2008 Mar;80(3):467-77
pubmed: 18205230
PLoS One. 2012;7(2):e32160
pubmed: 22384166
Intensive Care Med. 2016 Jan;42(1):28-37
pubmed: 26424680
JAMA Intern Med. 2020 Feb 1;180(2):272-273
pubmed: 31841575
Intensive Care Med Exp. 2019 May 18;7(1):28
pubmed: 31104220
Cell. 2013 Nov 21;155(5):1178-87
pubmed: 24267896
Rev Med Virol. 2010 Nov;20(6):372-9
pubmed: 20931610
Biomed J. 2015 Jan-Feb;38(1):70-6
pubmed: 25179711
Front Microbiol. 2018 Apr 10;9:686
pubmed: 29692764
J Infect. 2015 Jul;71(1):93-100
pubmed: 25749257
Indian J Crit Care Med. 2008 Oct;12(4):145-52
pubmed: 19742269
Front Immunol. 2019 Jan 08;9:3091
pubmed: 30671061
Nat Commun. 2019 Jul 19;10(1):3193
pubmed: 31324762
J Surg Res. 2012 Aug;176(2):571-82
pubmed: 22172138
Med Klin Intensivmed Notfmed. 2017 Apr;112(3):239-245
pubmed: 27435067
BMJ Open. 2017 Jun 21;7(6):e015734
pubmed: 28637738
Front Microbiol. 2019 Feb 07;10:16
pubmed: 30792698
Heliyon. 2020 Nov 21;6(11):e05535
pubmed: 33294681
Open Forum Infect Dis. 2017 Feb 13;4(2):ofx029
pubmed: 29497626
Semin Respir Crit Care Med. 2011 Aug;32(4):454-70
pubmed: 21858750
Semin Respir Crit Care Med. 2019 Aug;40(4):488-497
pubmed: 31585475
Intensive Care Med. 2017 Jul;43(7):1013-1020
pubmed: 28477143
Ann Med Interne (Paris). 1997;148(3):246-54
pubmed: 9255334
Crit Care. 2017 Aug 26;21(1):230
pubmed: 28841888
Crit Care Med. 2021 Nov 10;:
pubmed: 34534131
IET Syst Biol. 2016 Aug;10(4):153-66
pubmed: 27444025
PLoS One. 2012;7(12):e51340
pubmed: 23236477
Transplantation. 2020 May;104(5):e118-e124
pubmed: 31996662
J Oral Microbiol. 2013 Oct 25;5:
pubmed: 24167660
Front Med (Lausanne). 2020 May 15;7:188
pubmed: 32500076

Auteurs

François Mallet (F)

EA 7426 "Pathophysiology of Injury-Induced Immunosuppression" (Université Claude Bernard Lyon 1-Hospices Civils de Lyon-bioMérieux), Joint Research Unit HCL-bioMérieux, Immunology Laboratory & Anesthesia and Critical Care Medicine Department, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France.

Léa Diouf (L)

EA 7426 "Pathophysiology of Injury-Induced Immunosuppression" (Université Claude Bernard Lyon 1-Hospices Civils de Lyon-bioMérieux), Joint Research Unit HCL-bioMérieux, Immunology Laboratory & Anesthesia and Critical Care Medicine Department, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France.
IVIDATA, Levallois-Perret, France.

Boris Meunier (B)

EA 7426 "Pathophysiology of Injury-Induced Immunosuppression" (Université Claude Bernard Lyon 1-Hospices Civils de Lyon-bioMérieux), Joint Research Unit HCL-bioMérieux, Immunology Laboratory & Anesthesia and Critical Care Medicine Department, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France.
Soladis Inc., Cambridge, MA, United States.

Magali Perret (M)

BIOASTER Technology Research Institute, Lyon, France.

Frédéric Reynier (F)

BIOASTER Technology Research Institute, Lyon, France.

Philippe Leissner (P)

BIOASTER Technology Research Institute, Lyon, France.

Laurence Quemeneur (L)

Sanofi Pasteur, Sanofi, Marcy l'Etoile, France.

Andrew D Griffiths (AD)

Laboratoire de Biochimie (LBC), École Supérieure de Physique et de Chimie Industrielles de la ville de Paris (ESPCI) Paris, Paris Sciences & Lettres (PSL) Université, Centre National de la Recherche Scientifique (CNRS) UMR8231, Paris, France.

Virginie Moucadel (V)

EA 7426 "Pathophysiology of Injury-Induced Immunosuppression" (Université Claude Bernard Lyon 1-Hospices Civils de Lyon-bioMérieux), Joint Research Unit HCL-bioMérieux, Immunology Laboratory & Anesthesia and Critical Care Medicine Department, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France.

Alexandre Pachot (A)

EA 7426 "Pathophysiology of Injury-Induced Immunosuppression" (Université Claude Bernard Lyon 1-Hospices Civils de Lyon-bioMérieux), Joint Research Unit HCL-bioMérieux, Immunology Laboratory & Anesthesia and Critical Care Medicine Department, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France.

Fabienne Venet (F)

EA 7426 "Pathophysiology of Injury-Induced Immunosuppression" (Université Claude Bernard Lyon 1-Hospices Civils de Lyon-bioMérieux), Joint Research Unit HCL-bioMérieux, Immunology Laboratory & Anesthesia and Critical Care Medicine Department, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France.

Guillaume Monneret (G)

EA 7426 "Pathophysiology of Injury-Induced Immunosuppression" (Université Claude Bernard Lyon 1-Hospices Civils de Lyon-bioMérieux), Joint Research Unit HCL-bioMérieux, Immunology Laboratory & Anesthesia and Critical Care Medicine Department, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France.

Alain Lepape (A)

EA 7426 "Pathophysiology of Injury-Induced Immunosuppression" (Université Claude Bernard Lyon 1-Hospices Civils de Lyon-bioMérieux), Joint Research Unit HCL-bioMérieux, Immunology Laboratory & Anesthesia and Critical Care Medicine Department, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France.

Thomas Rimmelé (T)

EA 7426 "Pathophysiology of Injury-Induced Immunosuppression" (Université Claude Bernard Lyon 1-Hospices Civils de Lyon-bioMérieux), Joint Research Unit HCL-bioMérieux, Immunology Laboratory & Anesthesia and Critical Care Medicine Department, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France.

Lionel K Tan (LK)

GlaxoSmithKline, Brentford, United Kingdom.

Karen Brengel-Pesce (K)

EA 7426 "Pathophysiology of Injury-Induced Immunosuppression" (Université Claude Bernard Lyon 1-Hospices Civils de Lyon-bioMérieux), Joint Research Unit HCL-bioMérieux, Immunology Laboratory & Anesthesia and Critical Care Medicine Department, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France.

Julien Textoris (J)

EA 7426 "Pathophysiology of Injury-Induced Immunosuppression" (Université Claude Bernard Lyon 1-Hospices Civils de Lyon-bioMérieux), Joint Research Unit HCL-bioMérieux, Immunology Laboratory & Anesthesia and Critical Care Medicine Department, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH